Detalhe da pesquisa
1.
A genetic history of the pre-contact Caribbean.
Nature
; 590(7844): 103-110, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33361817
2.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
3.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
4.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
5.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
6.
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Cancer
; 129(7): 1017-1029, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715486
7.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol
; 203(4): 581-592, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608562
8.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol
; 98(10): E281-E284, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37515433
9.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol
; 98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665752
10.
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
Clin Infect Dis
; 75(9): 1503-1510, 2022 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35325094
11.
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
Mod Pathol
; 35(9): 1212-1219, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35504958
12.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153475
13.
Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.
Am J Hematol
; 97(1): 68-78, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716921
14.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Am J Hematol
; 97(8): 1035-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583199
15.
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Am J Hematol
; 97(12): 1560-1567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087091
16.
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
Am J Hematol
; 97(7): 865-876, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384048
17.
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
Am J Hematol
; 97(12): 1599-1606, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117258
18.
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Acta Haematol
; 145(5): 529-536, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717939
19.
New Approaches to Myelodysplastic Syndrome Treatment.
Curr Treat Options Oncol
; 23(5): 668-687, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320468
20.
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
Cancer
; 127(15): 2641-2647, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33823073